Immunity vs Cancer: Predicting who will gain from costly therapy
Cancer Immunity Biomarker

Immunity vs Cancer: Predicting who will gain from costly therapy

Dr. Talia Henkle
Dr. Talia Henkle

In 10 seconds? We continue our chat about cancer immune checkpoint therapies–which help our immune system attack cancer. One area showing progress is the quest for discrete biological features (AKA biomarkers) that indicate positive treatment outcomes in patients.

What’s the story? In our last Immunity vs Cancer digest, we learned that 'immune checkpoint inhibitors–or ICI'  have been game-changers in treating some advanced-stage cancers–with response rates (AKA improvement in cancer burden) that range from 10% to 60%.


Get unlimited access to our 3-min Digests and other premium features

Choose your plan:

Personal

$99/year

✅ Includes 7-day free trial for new users
✅ Weekly Recap
✅ Daily newsletter
✅ Access 4 topic areas of your choosing
✅ Access all citations and resources
✅ Gain background knowledge with a Quick Dive
✅ The Sparrow Sessions Podcast
✅ No ads
❌ Direct access to the Expert Network
❌ Your questions - answered by an Expert Scientist
❌ 12 hours of consultations with our fabulous experts per year (that’s 1 hour per month!)
❌ Access to all topic areas as we scale the Content Library

We'll send you a reminder email 3 days before your trial ends.

Start my free trial

Professional

$3499/year

✅ Includes 7-day free trial for new users
✅ Weekly Recap
✅ Daily newsletter
✅ Access all citations and resources
✅ Gain background knowledge with a Quick Dive
✅ The Sparrow Sessions Podcast
✅ No ads
✅ Direct access to the Expert Network
✅ Your questions - answered by an Expert Scientist
✅ 12 hours of consultations with our fabulous experts per year (that’s 1 hour per month!)
✅ Access to all topic areas as we scale the Content Library

We'll send you a reminder email 3 days before your trial ends.

Start my free trial